High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

被引:406
|
作者
Lisio, Michael-Antony [1 ]
Fu, Lili [1 ]
Goyeneche, Alicia [1 ]
Gao, Zu-hua [1 ]
Telleria, Carlos [1 ]
机构
[1] McGill Univ, Dept Pathol, Expt Pathol Unit, Montreal, PQ H3A 2B4, Canada
关键词
high-grade serous ovarian cancer; cortical inclusion cysts; serous tubular intra-epithelial carcinoma; ovarian surface epithelium; homologous recombination; BRCA; mutant p53; genetically-engineered mouse models; debulking surgery; chemotherapy; TUBAL INTRAEPITHELIAL CARCINOMA; OLAPARIB MAINTENANCE THERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; GROSS RESIDUAL DISEASE; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; TP53; MUTATIONS; DOUBLE-BLIND;
D O I
10.3390/ijms20040952
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
引用
收藏
页数:33
相关论文
共 50 条
  • [31] Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
    Kieffer, Yann
    Bonneau, Claire
    Popova, Tatiana
    Rouzier, Roman
    Stern, Marc-Henri
    Mechta-Grigoriou, Fatima
    FRONTIERS IN GENETICS, 2020, 11
  • [32] Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis
    Kobayashi, Hiroshi
    Ogawa, Kenji
    Kawahara, Naoki
    Iwai, Kana
    Niiro, Emiko
    Morioka, Sachiko
    Yamada, Yuki
    FREE RADICAL RESEARCH, 2017, 51 (9-10) : 755 - 764
  • [33] Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
    Abdallah, Reem
    Atallah, David
    Bitar, Nizar
    Chahine, Georges
    Ghanem, Hady
    Ghosn, Marwan
    Kattan, Joseph
    Nasr, Fadi
    Makdessi, Joseph
    Shamseddine, Ali
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 47
  • [34] Principles of dormancy evident in high-grade serous ovarian cancer
    Shepherd, Trevor G.
    Dick, Frederick A.
    CELL DIVISION, 2022, 17 (01)
  • [35] Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer
    Parkes, Eileen E.
    Kennedy, Richard D.
    ONCOLOGIST, 2016, 21 (05) : 586 - 593
  • [36] High-throughput approaches for precision medicine in high-grade serous ovarian cancer
    Govindarajan, Meinusha
    Wohlmuth, Christoph
    Waas, Matthew
    Bernardini, Marcus Q.
    Kislinger, Thomas
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [37] Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
    Wada, Miku
    Kukita, Asako
    Sone, Kenbun
    Hamamoto, Ryuji
    Kaneko, Syuzo
    Komatsu, Masaaki
    Takahashi, Yu
    Inoue, Futaba
    Kojima, Machiko
    Honjoh, Harunori
    Taguchi, Ayumi
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Tsuruga, Tetsushi
    Mori-Uchino, Mayuyo
    Wada-Hiraike, Osamu
    Osuga, Yutaka
    Fujii, Tomoyuki
    BIOMOLECULES, 2020, 10 (12) : 1 - 12
  • [38] In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
    Kim, Olga
    Park, Eun Young
    Klinkebiel, David L.
    Pack, Svetlana D.
    Shin, Yong-Hyun
    Abdullaev, Zied
    Emerson, Robert E.
    Coffey, Donna M.
    Kwon, Sun Young
    Creighton, Chad J.
    Kwon, Sanghoon
    Chang, Edmund C.
    Chiang, Theodore
    Yatsenko, Alexander N.
    Chien, Jeremy
    Cheon, Dong-Joo
    Yang-Hartwich, Yang
    Nakshatri, Harikrishna
    Nephew, Kenneth P.
    Behringer, Richard R.
    Fernandez, Facundo M.
    Cho, Chi-Heum
    Vanderhyden, Barbara
    Drapkin, Ronny
    Bast, Robert C., Jr.
    Miller, Kathy D.
    Karpf, Adam R.
    Kim, Jaeyeon
    PLOS GENETICS, 2020, 16 (06):
  • [39] Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
    Verhaak, Roel G. W.
    Tamayo, Pablo
    Yang, Ji-Yeon
    Hubbard, Diana
    Zhang, Hailei
    Creighton, Chad J.
    Fereday, Sian
    Lawrence, Michael
    Carter, Scott L.
    Mermel, Craig H.
    Kostic, Aleksandar D.
    Etemadmoghadam, Dariush
    Saksena, Gordon
    Cibulskis, Kristian
    Duraisamy, Sekhar
    Levanon, Keren
    Sougnez, Carrie
    Tsherniak, Aviad
    Gomez, Sebastian
    Onofrio, Robert
    Gabriel, Stacey
    Chin, Lynda
    Zhang, Nianxiang
    Spellman, Paul T.
    Zhang, Yiqun
    Akbani, Rehan
    Hoadley, Katherine A.
    Kahn, Ari
    Koebel, Martin
    Huntsman, David
    Soslow, Robert A.
    Defazio, Anna
    Birrer, Michael J.
    Gray, Joe W.
    Weinstein, John N.
    Bowtell, David D.
    Drapkin, Ronny
    Mesirov, Jill P.
    Getz, Gad
    Levine, Douglas A.
    Meyerson, Matthew
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (01) : 517 - 525
  • [40] Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?
    Wilczynski, Jacek
    Paradowska, Edyta
    Wilczynski, Milosz
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):